Myo Kardia Inc MYOK
We take great care to ensure that the data presented and summarized in this overview for MyoKardia Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MYOK
Top Purchases
Top Sells
About MYOK
Insider Transactions at MYOK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2020
|
Denelle J Waynick Chief Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,000
-100.0%
|
-
|
|
Nov 17
2020
|
Wendy L Yarno Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,508
-100.0%
|
-
|
|
Nov 17
2020
|
Anastasios Gianakakos President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
605,668
-100.0%
|
-
|
|
Nov 17
2020
|
Anastasios Gianakakos President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
141,405
-100.0%
|
-
|
|
Nov 17
2020
|
Mary B Cranston Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Kimberly J Popovits Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Mark L Perry Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
29,508
-100.0%
|
-
|
|
Nov 17
2020
|
Jake Bauer Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
90,209
-100.0%
|
-
|
|
Nov 17
2020
|
William Fairey EVP, Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,199
-100.0%
|
-
|
|
Nov 17
2020
|
Sunil Agarwal Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Nov 17
2020
|
Taylor C. Harris Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
42,559
-100.0%
|
-
|
|
Nov 17
2020
|
Robert Scott Mc Dowell Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
36,616
-100.0%
|
-
|
|
Nov 17
2020
|
David P Meeker Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,100
-100.0%
|
-
|
|
Feb 13
2019
|
Sanofi > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,168,899
-100.0%
|
$154,249,263
$37.66 P/Share
|
|
May 25
2018
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+3.47%
|
$7,350,000
$49.0 P/Share
|
|
Mar 07
2018
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-69.32%
|
-
|
|
Jan 03
2018
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
816,326
-54.55%
|
$34,285,692
$42.0 P/Share
|
|
Dec 06
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-40.94%
|
-
|
|
Sep 28
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-29.05%
|
-
|
|
Sep 26
2017
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
400,000
-5.49%
|
$17,200,000
$43.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders